PhenomeX Inc. provided earning guidance for the full year of 2023. for the period the company expects revenue to be in the range of $75 million to $85 million dollars with a gross margin target of approximately 65%.
Bruker Cellular Analysis, Inc.
Equities
BLI
US0843101017
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+53.18% | 63.85B | |
-2.18% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.50% | 26.52B | |
-21.40% | 18.69B | |
+2.81% | 12.73B | |
+22.74% | 12.11B | |
+27.31% | 12.07B |